Abstract
Treating two active malignancies concurrently can be exceedingly difficult. Complications can occur from the different treatment regimens, especially if they share common targets, and the progressing diseases can make managing treatment side-effects even more challenging. We report a case of a patient with coexisting CML and mRCC who progressed on multiple lines of mRCC therapy while experiencing significant dose limiting side-effects.
MeSH terms
-
Aged
-
Antineoplastic Agents / administration & dosage*
-
Carcinoma, Renal Cell / diagnosis
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / secondary*
-
Drug Delivery Systems / methods
-
Humans
-
Kidney Neoplasms / diagnosis
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / secondary*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
-
Male
-
Treatment Outcome